Lupine Partners with TTP plc UK for Soft Mist Inhalation Technology Platform
Lupine Inc., a wholly owned subsidiary of global pharmaceutical company Lupine Limited (Lupine) has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive global rights to develop, manufacture and market products from inhalation using TTP’s soft-technology platform for inhalation of fog. By leveraging this technology, Lupine hopes to provide healthcare professionals with alternative solutions to deliver affordable inhaled medicines to patients around the world.
Soft Mist Inhalation (SMI) technology enables inhalation drug delivery from a small, portable portable inhaler without the use of propellants. Individual doses are delivered using a precisely designed nozzle system to produce a cloud of slow, long-lasting aerosols. Lupine anticipates applications in respiratory care.
Lupine and TTP will jointly develop the device. Lupine will commercially manufacture the device through its network of internal and external manufacturing sites. Lupine will also develop and manufacture formulations to be delivered via the device, obtain the necessary regulatory approvals and market the products globally.
Commenting on the development, Vinita Gupta, Global CEO of Lupine, said, “Inhalation is a strategic pillar in Lupin’s growth story, as we strive to bring affordable medicines to patients around the world. The partnership with TTP for the SMI technology platform is a strategic addition to our broad inhalation capabilities. “
Alok Sonia, CEO – US Generics & Global RAD Head, Lupine added, “Lupine is delighted to partner with TTP. The organizations will work together to develop products using TTP’s SMI technology that complement Lupin’s complex inhalation product portfolio.
Commenting on the development, Sam Hyde, Managing Director of TTP, said: “We are delighted to partner with Lupine to commercialize our SMI technology so that it can benefit patients with chronic respiratory disease. TTP has deep expertise in aerosol science, and we have worked with our customers for over 30 years in the development of complex drug delivery devices – this partnership represents an exciting next step for us in this innovative area of administration of respiratory drugs. “
Lupine Limited shares were last trading in the BSE at Rs. 871.25 from the previous close of Rs. 885.85. The total number of shares traded during the day was 50,440 in over 3,710 trades.
The action hit an intraday high of Rs. 890.00 and an intraday low of 864.25. The net turnover during the day was Rs. 44,203,769.00.